Rapid Biosensor Systems announces a strategic agreement and collaboration on TB Diagnostics

Cambridge (UK) – January 2011 — Rapid Biosensor Systems Ltd (RBS) today announced that it has entered into a strategic agreement with Ortho Clinical Diagnostics, Inc., to bring RBS’s medical Breathalyser device for screening of active Tuberculosis into production. Under the agreement, Ortho Clinical Diagnostics will have an option on worldwide exclusive rights to commercialize the TB Breathalyser which is a device capable of detecting TB in less than 5 minutes from taking a cough sample.

Ortho Clinical Diagnostics will collaborate with RBS to complete the TB Breathalyser design for manufacture and will have the right to negotiate further terms in 2011/2012.

RBS has continued to successfully develop and patent its immunosensor platform technology which was tested for detecting TB in India and Ethiopia with good results and in an environment where the product will be needed at the point-of-care. The platform offers a low cost, portable, integrated solution which requires little training of the User. This whole non-invasive TB screening process is completed while the person waits for a few minutes and so if they are TB positive they can start treatment before they can spread the disease to others. Another huge benefit is that the TB Breathalyser test is not compromised by the presence of HIV.

The agreement with Ortho Clinical Diagnostics is exclusively for TB, however, the RBS platform can be adapted to other infectious diseases. “This collaboration will accelerate our plans to finalise the development of a world class medical device for minimising the spread of a killer disease. The TB Breathalyser that will be developed for manufacture should enable volume scale up and sales through established global channels in various clinical settings. This collaboration and the agreement allow us to focus on our strengths in developing medical devices and creating value by managing a strong IP portfolio” said Dennis Camilleri Co- Founder and Chief Executive Officer of Rapid Biosensor Systems.

About Rapid Biosensor Systems Ltd

Rapid Biosensor Systems Ltd is a privately owned company founded in Cambridge UK as a spin-out from the Sentec Consultancy. RBS is exploiting patented technology for rapid screening of infectious diseases. The Company moved to the Babraham Research Campus where much of its technology incubation was undertaken. The Company plans to explore device concepts based on its platform for other diseases including Bovine TB, Malaria and E.Coli which will facilitate business growth.

The Company had raised more than GB£1 million in capital from private Investors, government grants and a technology development award from the World Health Organisation.